The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

15 Mar 2016 07:00

RNS Number : 0611S
ProPhotonix Limited
15 March 2016

March 15, 2016

ProPhotonix Limited

聽("ProPhotonix" or "the Company")

PRELIMINARY RESULTS FOR THE YEAR ENDED DECEMBER 31, 2015

Annual General Meeting Date

ProPhotonix Limited (London Stock Exchange - AIM: PPIX, OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, today announces its unaudited preliminary results for the year ended December 31, 2015.

Annual General Meeting

The Company will hold the Annual General Meeting of the Shareholders on May 19, 2016 at 2:00 PM British Summer Time at the offices of K&L Gates LLP, One New Change, London EC4M 9AF. The Record date is set at March 24, 2016 for all shareholders of record.

Financial Highlights

Net Income of $0.3 million (2014: net loss $1.3 million)

EBITDA profit doubled to $1.2 million (2014: $0.6 million)

Operating income increased substantially to $0.8 million (2014: $0.1 million)

Gross profit margin improved to 41.4% (2014: 39.1%)

Gross profit decreased 7.1% to $6.0 million (2014: $6.4 million)

Revenue decreased 12.3% to $14.4 million (2014: $16.4 million) impacted by foreign currency exchange rate

Percentage revenue by market sectors: industrial 81%, medical 15%, and homeland security & defense 4%

Percentage revenue by geography: 47% Europe, 41% North America and 12% Rest of World

Available borrowing capacity of $2.0 million from its loan facilities at December 31, 2015.

Tim Losik, President & CEO, Commented:

"We entered 2015 with positive financial momentum from the prior year, but also with economic and foreign currency exchange rate headwinds. Neither of these challenges abated during the year making continuing financial success all the more meaningful. 2015 has again been a year of accomplishments in a number of respects - including our first full year of positive net income since 1994. We have now also achieved five consecutive half-yearly periods of positive EBITDA and three consecutive half-yearly periods of positive operating income. During 2015, operating income increased sevenfold and EBITDA increased 84%. In addition, the ProPhotonix team has been diligently pursuing new customers and new product and market initiatives, which helps set the stage for 2016."

Full Year 2015 Financial Results

Revenue fell by 12% during 2015, the year over year comparatives are significantly impacted by foreign currency conversion rates. While revenue for 2015 was $14.4 million, this would have been $15.8 million using constant currency exchange rates from 2014. Our margin rate improved to 41.4% resulting from a better product mix and continuing cost reductions. Operating expenses, excluding intangible amortization charges, totalled $5.2 million (2014: $6.2 million). Approximately 39% of the expense improvement was due to the impact of foreign currency fluctuations. Sales and marketing expenses were down 25% compared to last year at $1.8 million, while general and administrative and research and development expenses were reduced by approximately $0.4 million, or 12% over 2014. The Company achieved an operating profit of $0.8 million and EBITDA of $1.2 million. These factors contributed to ProPhotonix's financial improvement and positive net income of $0.3 million (2014: net loss $1.3 million). The balance sheet also continued to improve in 2015. Term debt declined $750,000 to $1,474,000 as at 31 December 2015, which is the lowest outstanding balance in more than a decade.

During 2015, order bookings declined 2.4% to $15.7 million from 2014, but the book-to-bill ratio increased to 1.09 (2014: 0.98). However, factoring in the impact of constant currency exchange rates from 2014, our order rate for 2015 would have been $17.3 million (a 7.6% improvement). Our backlog at December 31, 2015 was $5.6 million (2014: $5.6 million).

Customer and Product Development Initiatives:

In addition to the new customer activity in 2015, we entered into three (3) three-year supply agreements with customers and have received and fulfilled production orders for two of the three agreements beginning in Q4, 2015. We will begin commercial shipments on the third agreement in Q1 2016.

During the year, the ProPhotonix engineering team completed the development of several products and implemented a number of new technology capabilities. Furthermore, we announced eight new manufactured products. The Company filed four provisional/patent applications in 2015 as a continuation of intellectual property protection on our unique inventions and solutions.

Building toward the future:

Strategically, the Company is in transition. Our product development has historically been customer directed. This approach has served us well for specific applications and we continue to offer bespoke product solutions. However, we are now assessing various markets and product features in order to develop a product strategy focusing on specific markets to complement our direct customer engagement. We have identified two promising opportunities and we are concentrating our engineering talents in defined market areas that we believe are poised for fast market expansion.

The first of these is the UV LED and laser market for various applications including: printing, curing, 3D printing, bio-luminescence, medical microscopy, and other applications. Market research shows that the 2014 market size for UV LED applications was approximately $90 million with projected growth to $500 million by 2019, a compound average annual growth rate of nearly 40%. We have announced new products addressing this rapidly growing market and will continue with further product development.

Our other focus is on the continuing market requirement for multi-wavelength devices and systems; both laser and LED solutions. Increasingly, customers are seeking multi-wavelength solutions requiring innovative optics, complex electronics, on-board sensing capabilities, and sophisticated software control. We see opportunities which include a broad range of applications in microscopy, industrial, embedded camera and sensor calibration, solar simulators, optical sorting, and security markets. We are in the research and development phase of these products and expect to announce various laser and LED products in the future.

Strategy and Markets

ProPhotonix consists of two business units: an LED systems manufacturing business based in Ireland (Cork), and a laser modules production and laser diode distribution business located in the United Kingdom (Hatfield Broad Oak). Corporate headquarters and the North American sales activities are based in Salem, New Hampshire, USA. The fundamental strategy of the Company is growth in revenue through its existing customers, new customer activity, and new product and market expansion. ProPhotonix's short-term strategy has been to reach sustained positive EBITDA, cash flow, and net income. These continuing goals will be accomplished through a relentless focus on cost management and most importantly through revenue growth.

ProPhotonix's growth in the medium-term will be accomplished with new customer wins and the conversion of development orders into long run production orders. Prophotonix is also focused on expansion into new markets and new products. The Company continuously evaluates new product development and additions to the sales offering in an effort to increase customer satisfaction and provide solutions.

ProPhotonix sells its products principally into three markets: industrial (primarily machine vision illumination), medical, and homeland security and defense. The Company foresees growth opportunities in all three markets it serves which are briefly described below:

Industrial (Machine Vision)

Within the industrial market, machine vision is the term used to describe computerized analysis for controlling manufacturing processes, for example automated inspection. In terms of quality and speed, lighting is often a critical component in machine vision and the Company manufactures both LED systems and lasers designed specifically for this market. The recently enhanced 3D Pro Laser line generators and improved LED line light family specifically address this market.

Medical

The Company has experienced successes in the medical (including dental) market and has gained a foothold in the sector, supplying a variety of applications with current customers, including the world leader in stationary imaging equipment, a portable x-ray equipment manufacturer, a dental imaging manufacturer and also a pioneer in the manufacturing of devices offering eye tracking capability utilizing ProPhotonix's custom infrared LED arrays. The Company intends to broaden its product marketing effort in the medical field since it offers significant long-term revenue growth opportunities.

Homeland Security & Defense

LED systems, laser modules and laser diodes are used in a wide variety of applications in the security and defense fields. The Company currently supplies several defense sighting manufacturers in the US and Europe, as well as leading manufacturers of Auto Number Plate Recognition systems. This market offers significant growth opportunities for ProPhotonix over the next several years and the Company is currently marketing its laser and LED capabilities to additional security and optical character recognition systems companies in this market space.

Outlook

ProPhotonix begins 2016 in a strong position, having received production orders from the three customers who have signed three year supply agreements during 2015. We have also progressed our UV product family to include the COBRA Cure FX1, an innovative UV LED Curing system, which we recently announced. Recent booking trends, the macroeconomic environment and foreign exchange rate impacts cause us to be cautious for the first half of 2016, but we remain very positive about our business pipeline and confident in our ability to achieve continued positive momentum toward our profitability objectives.

Enquiries:

ProPhotonix Limited

Tim Losik, President and CEO

Tel: +1 603 893 8778

ir@prophotonix.com

Stockdale Securities Limited

Tom Griffiths and David Coaten

Tel: +44 (0) 20 7601 6100

Nominated Adviser and Broker

About ProPhotonix

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at聽www.prophotonix.comhttp://www.prophotonix.com/

PROPHOTONIX LIMITED

Consolidated Statements of Operations and Comprehensive Income (Loss)

($ in thousands except share and per share data)

Years Ended

December 31,

2015

(Unaudited)

2014

(Audited)

Revenue

$ 14,411

$ 16,431

Cost of Revenue

(8,441)

(10,006)

Gross Profit

5,970

6,425

Research & Development Expenses

(654)

(879)

Selling, General & Administrative Expenses

(4,526)

(5,350)

Amortization of Intangible Assets

-

(100)

Operating Income

790

96

Other Income, net

131

93

Foreign Currency Translation Losses

(259)

(1,031)

Warrant & Debt Acquisition Expense

(158)

(198)

Interest Expense

(224)

(300)

Income (Loss) Before Taxes

280

(1,340)

Income Taxes

-

-

Net Income (Loss)

$ 280

$ ( 1,340)

Other Comprehensive Income:

Foreign currency translation

170

958

Total Comprehensive Income / (Loss)

$ 450

$ ( 382)

Income (Loss) Per Share:

Basic and diluted:

Net Income (loss) per share

$0.003

($0.016)

Basic and diluted weighted average shares outstanding

83,665,402

83,665,402

FINANCIAL STATEMENTS

PROPHOTONIX LIMITED

CONSOLIDATED BALANCE SHEETS

聽($ in thousands except聽share聽and聽per聽share聽data)

December聽31

2015聽

(Unaudited)

2014

(Audited)

Assets

Current assets:

Cash and cash equivalents

$ 434

$ 331

Accounts receivable, less allowances of $21 in 2015 and $20 in 2014

2,751

2,606

Inventories

1,550

1,686

Prepaid expenses and other current assets

140

180

Total current assets

4,875

4,803

Net property, plant and equipment

132

184

Goodwill

385

429

Other long-term assets

81

36

Total assets

$ 5,473

$ 5,452

Liabilities and Stockholders' Equity / (Deficit)

Current liabilities:

Revolving credit facility

$ 1,334

$ 1,128

Current portion of long-term debt

966

668

Accounts payable

1,260

1,463

Accrued expenses

1,035

965

Total current liabilities

4,595

4,224

Long-term debt, net of current portion

508

1,585

Other long-term liabilities

178

178

Total liabilities

5,281

5,987

Stockholders' Equity / (Deficit):

Common stock, par value $0.001; shares authorized 250,000,000 at December 31, 2015 and at December 31, 2014; 83,665,402 shares issued and outstanding at December聽31, 2015 and at December聽31, 2014

84

84

Additional paid-in capital

111,860

111,583

Accumulated deficit

(112,734 )

(113,014 )

Accumulated other comprehensive income

982

812

Total stockholders' equity / (deficit)

192

(535)

Total liabilities and stockholders' equity

$ 5,473

$ 5,452

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

Years Ended聽December聽31

2015

(Unaudited)

2014

(Audited)

Cash flows from operating activities

Net income (loss)

$ 280

$ (1,340)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

277

280

Depreciation and amortization

101

258

Foreign exchange (gain) / loss

(51)

1,066

Amortization of debt discount and financing costs

130

186

Loss on disposal of assets

-

4

Provision for inventories

95

55

Provision for bad debts

4

5

Other changes in assets and liabilities:

Accounts receivable

(362)

(395)

Inventories

(127)

38

Prepaid expenses and other current assets

22

23

Accounts payable

(58)

100

Accrued expenses

136

(248)

Other assets and liabilities

(47)

(2)

Net cash provided by operating activities

400

30

Investing

Purchase of property, plant and equipment

(77 )

(64 )

Net cash used in investing activities

(77 )

(64 )

Financing

Borrowings of revolving credit facilities, net

312

144

Proceeds from issuance of debt

-

175

Principal repayment of long-term debt

(750 )

(292 )

Net cash (used in) provided by financing activities

(438)

27

Effect of exchange rate on cash

218

(64)

Net change in cash and equivalents

103

(71)

Cash and equivalents at beginning of period

331

402

Cash and equivalents at end of period

$ 434

$ 331

Supplemental cash flow information:

Cash paid for interest

$ 224

$ 303

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(in thousands)

Common聽Stock

AdditionalPaid inCapital

AccumulatedDeficit

Accumulated Other ComprehensiveIncome

TotalStockholders'Equity (Deficit)

Shares

Par$0.001

Balance December聽31, 2013 ......................................

83,665

$ 84

$ 111,302

$ (111,674)

$ (146)

$ (434)

Share based compensation, net of forfeitures ....................

-

-

280

-

-

280

Translation adjustment .....

-

-

-

-

958

958

Net Loss ...........................

-

-

-

(1,340)

-

(1,340)

Balance December聽31, 2014 ......................................

83,665

$ 84

$ 111,583

$ (113,014)

$ 812

$ (535)

Share based compensation, net of forfeitures ....................

-

-

277

-

-

277

Translation adjustment .....

-

-

-

-

170

170

Net Income .......................

-

-

-

280

-

280

Balance December聽31, 2015 ......................................

83,665

$ 84

$ 111,860

$ (112,734)

$ 982

$ 192

Notes to unaudited Preliminary Results

Basis of Presentation

The financial information set out in this document does not constitute the Company's statutory accounts for 2014 and 2015 or the Company's annual audited accounts for 2015 to be published and sent to its shareholders in accordance with Rule 19 of the AIM Rules for Companies. The 2015 accounts included herein are unaudited and therefore subject to change at the time the audited accounts are issued. The 2015 unaudited preliminary financial statements were prepared under US GAAP and were approved on March 14, 2016, by the Directors for issue on March 15, 2016. It is intended that the Company's 2015 annual report and audited accounts will be available to shareholders on or about April 7, 2016.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

Use of Non-GAAP Financial Measures

The Company provides non-GAAP financial measures, such as EBITDA, to complement its consolidated financial statements presented in accordance with GAAP. Non-GAAP financial measures do not have any standardized definition and, therefore, are unlikely to be comparable to similar measures presented by other reporting companies. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial and operating performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance, which management uses to evaluate financial performance for purposes of planning for future periods. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

The Company uses EBITDA (earnings before interest, taxes, depreciation, amortization, and stock-based compensation) as a non-GAAP financial measure in this press release. A reconciliation of net loss to EBITDA for the total year 2015 and 2014 is as follows:

(in thousands)

Year Ended December 31,

2015

2014

Net Income (Loss)

280

(1,340)

Plus:

Interest and other expense, net

510

1,436

Depreciation

101

158

Intangible asset amortization

-

100

Stock based compensation

277

280

Taxes

-

-

EBITDA profit

1,168

634

This information is provided by RNS
The company news service from the London Stock Exchange
END
FR AKQDNOBKDPND
Date   Source Headline
16th Dec 20217:00 amRNSSale of ProPhotonix and cancelation of AIM Listing
17th Nov 20217:00 amRNSNotice of GM
11th Nov 202111:05 amRNSSecond Price Monitoring Extn
11th Nov 202111:00 amRNSPrice Monitoring Extension
11th Nov 20217:00 amRNSProPhotonix Announces Merger Agreement
2nd Nov 20217:00 amRNSProPhotonix Extends COBRA HyperSpec range
14th Sep 20217:00 amRNSProPhotonix announces the new UV COBRA Cure FX4
8th Sep 20217:00 amRNS2021 Half-year Report
9th Jun 20217:00 amRNSPosting of Annual Report and Accounts
2nd Jun 20217:00 amRNSNew Wavelengths added to UVC LED System
25th Mar 20217:00 amRNSResults for the year ended December 31, 2020
26th Jan 20217:00 amRNSNew Hyperspectral COBRA MultiSpec LED Line Light
16th Nov 20202:05 pmRNSSecond Price Monitoring Extn
16th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSAdmission of Shares
10th Nov 20207:00 amRNSProPhotonix introduces 265nm UVC LED Lamp
9th Nov 20204:45 pmRNSResult of AGM and Director / PDMR Shareholdings
9th Oct 20207:00 amRNSPOSTING OF NOTICE OF ANNUAL GENERAL MEETING
8th Oct 20207:00 amRNSNew RGB-IR & RGB-White COBRA MultiSpec Line Lights
7th Oct 20203:07 pmRNSHolding(s) in Company
10th Sep 20207:00 amRNSINTERIM RESULTS FOR HALF YEAR ENDED JUNE 30, 2020
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
2nd Sep 20207:00 amRNSPROdigii Digital Lasers Range - 5 New Wavelengths
27th Aug 20207:00 amRNSRESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
25th Aug 20201:47 pmRNSNOTICE OF EXTENSION OF RIGHTS PLAN
24th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSChange of Adviser and Director Disclosures
29th Jun 20207:00 amRNSCustom LED Backlight wins VSD Innovators Award
23rd Jun 20207:00 amRNSAccounts Reporting Extension & Trading Update
30th Apr 20207:00 amRNSDirectorate Change
9th Apr 20207:00 amRNSCOVID – 19 and Trading Update
19th Mar 20207:00 amRNS3 Year Framework Product Supply & IP Agreement
16th Mar 20207:00 amRNSProPhotonix - UV LED Water Disinfection
16th Jan 20207:00 amRNSTrading Update 2019
26th Nov 20197:00 amRNSHolding(s) in Company
10th Oct 20197:00 amRNS5-Year Master Purchase Agreement - Fortune 50 CGLM
12th Sep 20197:00 amRNSProPhotonix to Exhibit UV Lamps at Labelexpo 2019
6th Sep 20197:00 amRNSProPhotonix issues Half-year Report
3rd Sep 20197:00 amRNSNew High-Powered Red Laser Diode from Ushio
31st May 201911:59 amRNSProPhotonix Notification of Major Holdings
31st May 201911:58 amRNSProPhotonix Notification of Major Holdings
24th May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
23rd May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
17th May 20197:00 amRNSProPhotonix Announces Trading Update
16th May 20195:58 pmRNSPPIX Announces AGM Results and PDMR Shareholdings
16th May 20197:00 amRNSPPIX Offers New COBRA Cure Mini UV Curing System
9th Apr 20197:00 amRNSProPhotonix Honored by Vision Systems Design 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.